Skip to main content

Certara Showcases 2024 Research Wins With Over 100 Papers Published

Written by Customer Service on . Posted in Public Companies.

The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list

RADNOR, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today showcases its impact on research by celebrating more than 100 publications secured in 2024 as well as the 12 Certara scientists included on the 2024 Stanford/Elsevier list, which highlights the top 2% of the most cited scientists across the globe.

Stanford/Elsevier’s Top 2% Scientist Ranking
Now in its 7th iteration, the Stanford/Elsevier’s Top 2% Scientist Ranking list includes the top and most-cited researchers globally in 22 scientific disciplines and 174 sub-disciplines and encompasses standardized data on citations, h-index, and a wide range of bibliometric indicators. The following Certara researchers appeared on Elsevier’s top 2% of the world’s most-cited researchers list in 2024, highlighting recent and career-long impacts.

  • Amin Rostami-Hodjegan, Chief Scientific Officer at Simcyp
  • Frederic Bois, Senior Scientific Advisor & Head of Mechanistic Modelling
  • Hannah Jones, Senior Vice President, Head of Simcyp PBPK Modelling Services
  • Hugo Geerts, Head of QSP Neurosciences  
  • Khaled Abduljalil, Senior Principal Scientist at Simcyp
  • Karen Rowland-Yeo, Senior Vice President, Client & Regulatory Strategy
  • Masoud Jamei, Senior Vice President of Research and Development at Simcyp
  • Piet H van der Graaf, Senior Vice President and Head of Quantitative Systems Pharmacology  
  • Patrick Smith, President of Certara Drug Development Solutions   
  • Rajesh Krishna, Distinguished Scientist, Drug Development Science
  • Stephen Duffull, Senior Scientific Advisor
  • Trevor Johnson, Principal Scientist at Simcyp

“Certara is a science-driven organization, and our scientists are world leaders in their fields. Our clients rely on us to deliver advanced biosimulation software and the expert advice needed to interpret results for optimal strategic decision-making,” said William Feehery, CEO, Certara.

2024 Publications
Certara scientists and publications span the entire drug discovery and development process from early discovery through clinical, regulatory, and post-approval. Key highlights and trends evident in 2024 publications are grouped into two primary categories below.

Value and Impact of Biosimulation Strategies and Execution in Drug Development

  • Pediatric oncology drug development and dosage optimization
  • Mechanistic modeling’s impact on first-in-human dose predictions and clinical validations thereof
  • Exposure-Response Analyses to Inform Dosing Considerations and Labeling
  • Impact of physiologically-based pharmacokinetics (PBPK) modeling on Global Health
  • The role of pharmacometrics in understanding Variability in Clinical Trials
  • Extended Model-Informed Drug Development: Beyond Clinical Trials and Regulatory Approval

Best practices for implementing technologies that streamline drug submission and approval processes

  • Diversity in Clinical Trial Enrollment and meeting requirements of the FDA Diversity Action Plan
  • Using real-world data to inform clinical patient management and treatment guidelines for COVID-19
  • Unlocking the Synergies of Generative AI in Regulatory Writing
  • Preventing chaos: The Critical Role of the Submission Lead

To learn more about Certara’s publications, please visit: www.certara.com/resources/publication

About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.

Certara Contact:
Sheila Rocchio
sheila.rocchio@certara.com

Media Contact:
Alyssa Horowitz
certara@pancomm.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.